Trial Profile
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs CAR-T cell therapies (Primary)
- Indications Haematological malignancies; Leukaemia; Lymphoma; Multiple myeloma
- Focus Therapeutic Use
- Sponsors Hebei Senlang Biotechnology
- 14 Dec 2021 Results (n=64 ) from NCT03173417, NCT02546739, NCT03312205 and NCT03671460; analysing factors associated with efficacy following CD19 CAR-T therapy among B-ALL patients with TP53 mutation/chromosome 17p deletion, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 21 Oct 2017 New trial record